News | January 23, 2012

Pregnant Women With Life-Threatening Blood Clots Should Receive Aggressive Treatment

January 23, 2012 — Pregnant women who develop dangerous blood clots in the leg often forgo the most effective treatment for fear of harming the baby. Yet treatment to remove the clot is not only safe, it can prevent serious problems, including death, suggests research being presented at the 24th International Symposium on Endovascular Therapy (ISET).

Deep vein thrombosis (DVT) – a blood clot that forms deep in the thigh – is four to six times more common in pregnant women than those who are not pregnant. A smaller blood clot can break off and travel to the lung artery causing a pulmonary embolism. When DVT is not treated early and effectively, the clot can become permanent, causing lifelong pain and blood flow problems. The most effective treatments include the minimally invasive delivery of clot-dissolving drugs directly to the clots to break them up, or surgery.

The study included 11 pregnant women with DVT. Nine were treated with minimally invasive techniques by guiding a tiny tube called a catheter to the site of the clot to deliver a bath of clot-dissolving drugs, and two had surgery to remove the clot. Treatment successfully broke up the clot in all cases. All but one of the pregnancies resulted in a successful birth. One woman in her second trimester miscarried a week after treatment. The woman suffers from antiphospholipid antibody syndrome, which causes the blood to clot abnormally and increases the risk of miscarriage, so the condition likely was the cause of her miscarriage in this case as well, researchers said. Three of the women had successful subsequent pregnancies.

Pregnant women who develop DVT are typically treated less aggressively with blood thinners, which rarely clear the clot.

“Pulmonary embolism is the second most frequent cause of death in pregnant women in North America and the United Kingdom,” said Anthony Comerota, M.D., director of the Jobst Vascular Center at The Toledo Hospital, Ohio. “Physicians should use more effective treatment to prevent these women from having serious life-long problems that can affect their ability to care for their children.”

For more information: www.iset.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init